Drug Trial Radar · NCT06618196
Study to Evaluate the Immunogenicity of LR20062 Compared to Control When Administered Intramuscularly in Healthy Infants At 2, 4, 6 Months of Age
Last checked: Nov 19, 2026Latest source record: Oct 1, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
336
Planned (sponsor's estimate)
Start
Oct 2, 2024
Primary completion
Jun 30, 2025
Study completion Apr 30, 2026
Sponsor
- Lead sponsor
- LG ChemIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 days, up to 70 days
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a phase II, randomized, double-blind, active-controlled, parallel-group, multicenter study to evaluate the immunogenicity and safety of DTaP-HepB-IPV-Hib hexavalent vaccine LR20062 in healthy infants as primary series at 2, 4, 6 months of age.
Conditions
- Diphtheria
- Tetanus
- Pertussis
- Hepatitis B
- Poliomyelitis
- Haemophilus Influenzae Type B Infection
Interventions
LR20062Biological
DTaP-HepB-IPV-Hib vaccine
DTaP-HepB-IPV-Hib vaccineBiological
Control hexavalent vaccine
Primary outcomes
What the sponsor says the trial is designed to measure.
- Seroprotection/vaccine-response rateTime frame: 1 month after the third dose primary series
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.